Synthetic analog · 30 amino acids · 3,647.2 Da

CJC-1295 (with DAC) studies and research data

PepBank has 21 CJC-1295 studies with results. 10 of them gave CJC-1295, with 43 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 43 results and 36 papers. Newer studies from Europe PMC

Results in people

47% of 43 results

Results in animals

47% of 43 results

Results in lab cells

7% of 43 results

From computer models

0% of 43 results

The molecule

CJC-1295 identity

Identifiers, parent molecule, targets and development stage, from curated data.

CJC-1295 is a 30-residue analogue of human growth hormone-releasing factor, hGRF(1-29). It carries four changes to the native 1-29 sequence (D-Ala2, Gln8, Ala15, Leu27) and an added C-terminal lysinamide whose side chain bears a 3-maleimidopropionamide group, the drug affinity complex (DAC). The maleimide reacts with the free thiol of Cys34 on serum albumin after injection, which extends the plasma life of the peptide; ConjuChem scientists reported this in rats in 2005 (PMID 15817669) and a half-life of 5.8 to 8.1 days in healthy adults in 2006 (PMID 16352683). Development stopped at phase 2 and no regulator has approved it. In FDA documents this record is 'CJC-1295 DAC'; FDA uses 'CJC-1295 (free base)' for the 29-residue form without DAC (see the Mod GRF (1-29) record).

Kind: Synthetic analog · 30 residues
Identifiers: PubChem CID91971820 (opens in a new tab)UNII62RC32V9N7 (opens in a new tab)CAS446262-90-4
Parent: Analog of Somatorelin, human GHRH(1-44) · residues 32-60Jette et al. 2005 identify CJC-1295 as a tetrasubstituted form of hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus. The 29-residue core matches mature somatoliberin 1-29 at every other position.
Development: Phase 2ConjuChem (Montreal)Teichman et al. 2006 (PMID 16352683) report two randomised placebo-controlled dose-ascending studies in healthy adults. ClinicalTrials.gov NCT00267527, a phase 2 study of CJC 1295 in HIV patients with visceral obesity (ConjuChem, 120 participants listed, 2005-12 to 2006-09), has status TERMINATED and gives no reason. FDA's briefing document of 2024-12-04 relays an anecdotal, unpublished report of a ConjuChem phase 2 trial in HIV lipodystrophy: 192 subjects were enrolled; after the 11th weekly dose one subject had chest discomfort, an acute myocardial infarction was confirmed and the subject died; the attending physician's most likely explanation was asymptomatic coronary artery disease with plaque rupture and occlusion; the study was terminated and its data were not published. The briefing does not name the trial, and its participant number (192) differs from the registry (120), so the link to NCT00267527 is not confirmed. FDA says the published human data come from 63 healthy adults in three studies (Teichman 2006, Ionescu and Frohman 2006, Sackmann-Sala 2009) and that it found no published study in which patients with the conditions it reviewed (Prader-Willi syndrome, Turner syndrome, small for gestational age, idiopathic short stature, HIV lipodystrophy, wasting, severe burns) received these substances. No later study was found. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Growth hormone-releasing hormone receptorGHRHRQ02643 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

30 amino acids · 6 modifications

H-

YDAIFTSY

RKVLQLSAR

KLLQDISR

Alignment to Somatorelin, human GHRH(1-44)

Calculated from the two sequences. Curated notes are shown as given.

25 of 30 aligned residues identical (83%) · 4 substitutions · 1 non-canonical residue · Somatorelin, human GHRH(1-44) 1–30

Top row: Somatorelin, human GHRH(1-44) (parent)
Bottom row: CJC-1295 (with DAC)

YDAIFTSY

RKVLQLSAR

KLLQDISR

Same as parent
Substituted
Non-canonical or D-form
Added
Gap
Modified side chain or end
Parent context

Differences from the parent

1Parent 2 · analog 2Ala → D-Ala · D-amino acidL-Ala replaced by D-Ala. Stated aim: resistance to dipeptidyl peptidase-IV cleavage (FDA briefing, citing Jette et al. 2005). GSRS writes the subunit as YaDAIFTQSYRKVLAQLSARKLLQDILSRK; the lowercase a is D-Ala.
2Parent 8 · analog 8Asn → Gln · SubstitutionAsn8 replaced by Gln8. Stated aim: avoid asparagine rearrangement and hydrolysis (FDA briefing, citing Jette et al. 2005). Asn8 of native hGRF(1-29) replaced by Gln.
3Parent 15 · analog 15Gly → Ala · SubstitutionGly15 replaced by Ala15. Gly15 of native hGRF(1-29) replaced by Ala.
4Parent 27 · analog 27Met → Leu · SubstitutionMet27 replaced by Leu27. Stated aim: prevent methionine oxidation (FDA briefing, citing Jette et al. 2005). Met27 of native hGRF(1-29) replaced by Leu.
5Parent 30 · analog 30Gln → Lys · Substitution3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamide (3-maleimidopropionamide) on the Lys30 side-chain amine. GSRS records this as a structural modification at residue 30 using fragment UNII X92FEQ3194. The maleimide binds Cys34 of serum albumin. C-terminal lysinamide.

Basis: Jette et al. 2005 identify CJC-1295 as a tetrasubstituted form of hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus. The 29-residue core matches mature somatoliberin 1-29 at every other position.

Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.

Properties

From identity sources

Formula: C₁₆₅H₂₆₉N₄₇O₄₆
Molecular weight: 3,647.2 g/mol
Monoisotopic mass: 3,645.0155 Da

GSRS UNII 62RC32V9N7(opens in a new tab)retrieved 2026-10-09
PubChem CID 91971820(opens in a new tab)retrieved 2026-10-09
Curated formula check(opens in a new tab)retrieved 2026-10-09
Curated FDA PCAC briefing document 2024-12-04, Table 1 (CJC-1295 DAC)(opens in a new tab)retrieved 2026-10-09

Calculated from the sequence

pKa set

Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): −0.207; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 2,980 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp: ExPASy reports more than 10 % error without Trp.
Instability index: 45.69; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 114.0; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.99 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.611; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984

Not included: albumin-binding group. Mass, charge and pI are not calculated; use the identity-source values.
D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Composition

Hydrophobic40% (12)A I L V
Aromatic10% (3)F Y
Positive20% (6)K R
Negative7% (2)D
Polar23% (7)Q S T

30 residues. Each residue counts in one class; F and W count as aromatic.

A Ala4 · 13%

I Ile2 · 7%

L Leu5 · 17%

M Met0 · 0%

V Val1 · 3%

F Phe1 · 3%

W Trp0 · 0%

Y Tyr2 · 7%

H His0 · 0%

K Lys3 · 10%

R Arg3 · 10%

D Asp2 · 7%

E Glu0 · 0%

N Asn0 · 0%

Q Gln3 · 10%

S Ser3 · 10%

T Thr1 · 3%

C Cys0 · 0%

G Gly0 · 0%

P Pro0 · 0%

3D structure

PredictedAlphaFold DB · P01286

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

CJC-1295 (with DAC) has 30 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 91971820(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.150
μH, best 11-residue window: 0.611
Arrow direction: 77°
Residues: 30 · 2 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	Y	0°	0.26
2	A	100°	0.62
3	D	200°	-0.90
4	A	300°	0.62
5	I	40°	1.38
6	F	140°	1.19
7	T	240°	-0.05
8	Q	340°	-0.85
9	S	80°	-0.18
10	Y	180°	0.26
11	R	280°	-2.53
12	K	20°	-1.50
13	V	120°	1.08
14	L	220°	1.06
15	A	320°	0.62
16	Q	60°	-0.85
17	L	160°	1.06
18	S	260°	-0.18
19	A	0°	0.62
20	R	100°	-2.53
21	K	200°	-1.50
22	L	300°	1.06
23	L	40°	1.06
24	Q	140°	-0.85
25	D	240°	-0.90
26	I	340°	1.38
27	L	80°	1.06
28	S	180°	-0.18
29	R	280°	-2.53
30	K	20°	-1.50

Results by area

CJC-1295 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

21 of 36 studies have results (58%), published 2005 to 2026. Top row: every study. Bottom row: studies with results about CJC-1295 (with DAC), by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies36 in all, 2005 to 2026

Studies with results21 in all, 2005 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

CJC-1295 studies on growth hormone and growth

27 results · people 16 · animals 10 · lab 1

Top 3 of 27 results

In healthy adults, one CJC‑1295 injection raised growth hormone levels 2- to 10-fold for 6 days or more, with larger doses giving larger rises.The Journal of clinical endocrinology and metabolism, 2006
In healthy young men, an apolipoprotein A1 form in the blood decreased one week after a CJC‑1295 injection.Growth hormone & IGF research, 2009
In healthy men, one CJC‑1295 injection raised average growth hormone levels by 46% a week later.The Journal of clinical endocrinology and metabolism, 2006

CJC-1295 studies on use, access and costs

2 results · people 2 · animals 0 · lab 0

2 results

In online forum threads, women said they used CJC‑1295 for weight loss, muscle gain, younger-looking skin, better sleep and injury healing. These are user claims.Substance use & misuse, 2016
In online forum threads, women raised concerns about dosing, cycling and long-term effects of CJC‑1295 use. These are user concerns, not measured harms.Substance use & misuse, 2016

CJC-1295 studies on blood levels and clearance

7 results · people 1 · animals 5 · lab 1

Top 3 of 7 results

In healthy adults, CJC‑1295 stayed in the body for a long time, with an estimated half-life of 5.8 to 8.1 days.The Journal of clinical endocrinology and metabolism, 2006
In rats, CJC‑1295 stayed in the blood for more than 72 hours.Endocrinology, 2005
In rats, the intact peptide, including CJC‑1295, could be found in blood for at least 4 hours after injection.Analytical and bioanalytical chemistry, 2016

CJC-1295 studies on side effects

1 result · people 1 · animals 0 · lab 0

1 result

In healthy adults given CJC‑1295, no serious adverse reactions were reported.The Journal of clinical endocrinology and metabolism, 2006

CJC-1295 studies on weight and appetite

4 results · people 0 · animals 4 · lab 0

Top 3 of 4 results

In GHRH knockout mice, CJC‑1295 given daily gave normal body weight.American journal of physiology. Endocrinology and metabolism, 2006
In GHRH knockout mice, CJC‑1295 every 48 or 72 hours gave higher body weight than placebo, but not fully normal growth.American journal of physiology. Endocrinology and metabolism, 2006
In GHRH knockout mice, lean mass was normal in all groups given CJC‑1295.American journal of physiology. Endocrinology and metabolism, 2006

CJC-1295 studies on bones and joints

1 result · people 0 · animals 1 · lab 0

1 result

In GHRH knockout mice, thigh and shin bone length stayed normal with CJC‑1295 every 1 or 2 days.American journal of physiology. Endocrinology and metabolism, 2006

CJC-1295 studies on receptors and cell signals

1 result · people 0 · animals 0 · lab 1

1 result

In lab tests, ghrelin mimics such as CJC‑1295 acted more like blockers of ghrelin binding to its receptor, while cannabinoids made this binding stronger.Talanta, 2022

Trials and papers

CJC-1295 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

1 trial match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (1 of 1)

1 trial · 1 stopped early

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

200520062007

Ph 2
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
NCT00267527
Dec 2005 to Sept 2006
Terminated
Terminated

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2NCT00267527

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

ConjuChemn = 120Dec 2005 to Sept 2006

Obesity · HIV Infections

Trial page ClinicalTrials.govUpdated 16 Oct 2006

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

36 studies match. Retracted studies are left out.

Showing 19 of 36 studiesquery qry_cf6b522146df1388430b9020

Studies with results

21 studies in all, 19 on this page

Not a test of CJC-1295 (with DAC) alone · 2012

1 result

Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.

Thomas et al. 2012Methods (San Diego, Calif.)cited by 75

PMID 21871962DOI 10.1016/j.ymeth.2011.08.009PUB-21871962

Full text at the publisher1 result where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Publisher page See results (1)

Not a test of CJC-1295 (with DAC) alone · 2010

1 result

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.

Henninge et al. 2010Drug testing and analysiscited by 51

PMID 21204297DOI 10.1002/dta.233PUB-21204297

Full text at the publisher1 result where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Publisher page See results (1)

Animal study (in vivo) · rat · 2005

5 results

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Jetté et al. 2005Endocrinologycited by 30

PMID 15817669DOI 10.1210/en.2004-1286PUB-15817669

Full text at the publisher5 results where CJC-1295 (with DAC) was given

Publisher page See results (5)

Animal study (in vivo) · mouse · 2009

4 results

Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.

Gautam et al. 2009Proceedings of the National Academy of Sciences of the United States of Americacited by 30

PMID 19332789PMC2662962DOI 10.1073/pnas.0900977106PUB-19332789

Rights unknown4 results where CJC-1295 (with DAC) was given

Source link See results (4)

Animal study (in vivo) · rat · 2016

12 results

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

Knoop et al. 2016Analytical and bioanalytical chemistrycited by 29

PMID 26879649PMC4830873DOI 10.1007/s00216-016-9377-3PUB-26879649

CC BY2 results where CJC-1295 (with DAC) was given (plus 1 on tools or combinations, listed separately)

Download PDF See results (12)

Randomized controlled trial · 2006

5 results

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Teichman et al. 2006The Journal of clinical endocrinology and metabolismcited by 28

PMID 16352683DOI 10.1210/jc.2005-1536PUB-16352683

Rights unknown5 results where CJC-1295 (with DAC) was given

Source link See results (5)

Non-randomized trial · 2009

6 results

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Sackmann-Sala et al. 2009Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Societyn = 11cited by 26

PMID 19386527PMC2787983DOI 10.1016/j.ghir.2009.03.001PUB-19386527

Rights unknown6 results where CJC-1295 (with DAC) was given

Source link See results (6)

Non-randomized trial · 2006

7 results

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Ionescu et al. 2006The Journal of clinical endocrinology and metabolismcited by 25

PMID 17018654DOI 10.1210/jc.2006-1702PUB-17018654

Full text at the publisher7 results where CJC-1295 (with DAC) was given

Publisher page See results (7)

Not a test of CJC-1295 (with DAC) alone · 2013

12 results

Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.

Kwok et al. 2013Analytical and bioanalytical chemistrycited by 25

PMID 23318763DOI 10.1007/s00216-012-6697-9PUB-23318763

Full text at the publisher2 results where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Publisher page See results (12)

Not a test of CJC-1295 (with DAC) alone · 2021

6 results

Advances in the detection of growth hormone releasing hormone synthetic analogs.

Memdouh et al. 2021Drug testing and analysiscited by 16

PMID 34665524DOI 10.1002/dta.3183PUB-34665524

Full text at the publisher2 results where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Publisher page See results (6)

Animal study (in vivo) · mouse · 2006

10 results

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Alba et al. 2006American journal of physiology. Endocrinology and metabolismcited by 12

PMID 16822960DOI 10.1152/ajpendo.00201.2006PUB-16822960

Full text at the publisher10 results where CJC-1295 (with DAC) was given

Publisher page See results (10)

Observational study · 2016

2 results

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

Van Hout et al. 2016Substance use & misusecited by 10

PMID 26771670DOI 10.3109/10826084.2015.1082595PUB-26771670

Full text at the publisher2 results where CJC-1295 (with DAC) was given

Publisher page See results (2)

Not a test of CJC-1295 (with DAC) alone · 2020

7 results

Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

Pont et al. 2020Journal of chromatography. Acited by 7

PMID 32971474DOI 10.1016/j.chroma.2020.461548PUB-32971474

Full text at the publisher2 results where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Publisher page See results (7)

Not a test of CJC-1295 (with DAC) alone · 2022

5 results

Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

Thomas et al. 2022Analytical science advancescited by 7

PMID 38716080PMC10989627DOI 10.1002/ansa.202200027PUB-38716080

Free to read · publisher termsCC BY-NC1 result where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Read at source See results (5)

Animal study (in vivo) · horse · 2019

3 results

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

Timms et al. 2019Drug testing and analysiscited by 4

PMID 30489688DOI 10.1002/dta.2554PUB-30489688

Full text at the publisher1 result where CJC-1295 (with DAC) was given (plus 2 on tools or combinations, listed separately)

Publisher page See results (3)

Other design · 2022

2 results

Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

Danila et al. 2022Talantacited by 4

PMID 34736642DOI 10.1016/j.talanta.2021.122905PUB-34736642

Full text at the publisher1 result where CJC-1295 (with DAC) was given (plus 1 on tools or combinations, listed separately)

Publisher page See results (2)

Not a test of CJC-1295 (with DAC) alone · 2024

5 results

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Thomas et al. 2024Journal of mass spectrometry : JMScited by 4

PMID 38197510DOI 10.1002/jms.4996PUB-38197510

Free to read · publisher termsCC BY-NC-ND1 result where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Read at source See results (5)

Not a test of CJC-1295 (with DAC) alone · 2022

10 results

An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

Coppieters et al. 2022Journal of pharmaceutical and biomedical analysiscited by 3

PMID 35298973DOI 10.1016/j.jpba.2022.114726PUB-35298973

Full text at the publisher3 results where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Publisher page See results (10)

Not a test of CJC-1295 (with DAC) alone · 2023

8 results

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Cristea et al. 2023Analytical biochemistrycited by 3

PMID 37806509DOI 10.1016/j.ab.2023.115336PUB-37806509

Full text at the publisher2 results where CJC-1295 (with DAC) was a tool, carrier or part of a combination

Publisher page See results (8)

No result for CJC-1295 (with DAC) (6 studies on this page, 11 in all)

These studies name CJC-1295 (with DAC) but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Validation Study · 2015

6 results

Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

Thomas et al. 2015Drug testing and analysiscited by 31

PMID 26382721DOI 10.1002/dta.1868PUB-26382721

Full text at the publisher6 results

Publisher page See results (6)

PubMed tag: none · 2014

Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.

Thevis et al. 2014Expert review of proteomicscited by 20

PMID 25382550DOI 10.1586/14789450.2014.965159PUB-25382550

Full text at the publisher

Publisher page

PubMed tag: none · 2016

The study of doping market: How to produce intelligence from Internet forums.

Pineau et al. 2016Forensic science internationalcited by 8

PMID 27710891DOI 10.1016/j.forsciint.2016.09.017PUB-27710891

Full text at the publisher

Publisher page

PubMed tag: Review · 2026

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield et al. 2026The American journal of sports medicinecited by 3

PMID 41476424DOI 10.1177/03635465251357593PUB-41476424

Full text at the publisher

Publisher page

PubMed tag: Review · 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias et al. 2026Sports medicine (Auckland, N.Z.)cited by 3

PMID 41966639DOI 10.1007/s40279-026-02437-0PUB-41966639

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2026

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Mavrych et al. 2026Frontiers in agingcited by 3

PMID 42021992PMC13095733DOI 10.3389/fragi.2026.1790247PUB-42021992

CC BY

Download PDF

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

CJC-1295 (with DAC) studies: 21 papers with results

Page 1 of 1

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL · The Journal of clinical endocrinology and metabolism · 2006
Randomized controlled trial · 5 results
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Sackmann-Sala L · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009
Non-randomized trial · 6 results
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Ionescu M · The Journal of clinical endocrinology and metabolism · 2006
Non-randomized trial · 7 results
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Van Hout MC · Substance use & misuse · 2016
Observational study · 2 results
Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.
Gautam D · Proceedings of the National Academy of Sciences of the United States of America · 2009
Animal study (in vivo) · mouse · 4 results
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
Jetté L · Endocrinology · 2005
Animal study (in vivo) · rat · 5 results
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
Knoop A · Analytical and bioanalytical chemistry · 2016
Animal study (in vivo) · rat · 12 results
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
Alba M · American journal of physiology. Endocrinology and metabolism · 2006
Animal study (in vivo) · mouse · 10 results
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Timms M · Drug testing and analysis · 2019
Animal study (in vivo) · horse · 3 results
Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.
Danila GM · Talanta · 2022
Other design · 2 results
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
Coppieters G · Journal of pharmaceutical and biomedical analysis · 2022
Not a test of CJC-1295 (with DAC) alone · 10 results
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Uçaktürk E · Journal of pharmaceutical and biomedical analysis · 2026
Not a test of CJC-1295 (with DAC) alone · 9 results
Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.
Kwok WH · Analytical and bioanalytical chemistry · 2013
Not a test of CJC-1295 (with DAC) alone · 12 results
Advances in the detection of growth hormone releasing hormone synthetic analogs.
Memdouh S · Drug testing and analysis · 2021
Not a test of CJC-1295 (with DAC) alone · 6 results
Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
Pont L · Journal of chromatography. A · 2020
Not a test of CJC-1295 (with DAC) alone · 7 results
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
Cristea CD · Analytical biochemistry · 2023
Not a test of CJC-1295 (with DAC) alone · 8 results
Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
Thomas A · Methods (San Diego, Calif.) · 2012
Not a test of CJC-1295 (with DAC) alone · 1 result
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.
Henninge J · Drug testing and analysis · 2010
Not a test of CJC-1295 (with DAC) alone · 1 result
Probing for peptidic drugs (2-10 kDa) in doping control blood samples.
Thomas A · Analytical science advances · 2022
Not a test of CJC-1295 (with DAC) alone · 5 results
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Thomas A · Journal of mass spectrometry : JMS · 2024
Not a test of CJC-1295 (with DAC) alone · 5 results
A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Timms M · Drug testing and analysis · 2019
Not a test of CJC-1295 (with DAC) alone · 1 result

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	No Drugs@FDA record (openFDA drugsfda searches for CJC-1295 on 2026-10-09 returned no matches). FDA states that compounded drugs containing CJC-1295 may pose an immunogenicity risk for certain routes and may raise peptide-impurity and characterisation problems, that it has identified serious adverse events including increased heart rate and a systemic vasodilatory reaction, and that available clinical data are limited.	9 Oct 2026	fda.gov (opens in a new tab)
EU	EMA	No match for CJC-1295 in the EMA medicines data file or the EMA orphan designation data file, both downloaded 2026-10-09 (medicines file timestamp 2026-10-09T06:23:44Z, 2,746 records; orphan designations file timestamp 2026-10-09T06:32:20Z, 3,310 records). National authorisations were not checked.	9 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S2.2.4) Named in S2.2.4 as a GHRH analogue (with CJC-1293) and indexed on page 8.	2026 List	wada-ama.org (opens in a new tab)
World (WADA 2027 list)	Note	The 2027 Prohibited List, in force from 2027-01-01, names CJC-1295 in S2.2.4.	9 Oct 2026	wada-ama.org (opens in a new tab)

Safety outcomes

2 safety results for CJC-1295 (with DAC).

Reported by FDA, not confirmed in a study

FDA's briefing document of 2024-12-04 relays an anecdotal, unpublished report of a ConjuChem phase 2 trial in HIV lipodystrophy: 192 subjects were enrolled; after the 11th weekly dose one subject had chest discomfort, an acute myocardial infarction was confirmed and the subject died; the attending physician's most likely explanation was asymptomatic coronary artery disease with plaque rupture and occlusion; the study was terminated and its data were not published. The briefing does not name the trial, and its participant number (192) differs from the registry (120), so the link to NCT00267527 is not confirmed.

This is a report about CJC-1295 (with DAC), not a study result. Source: FDA briefing document, CJC-1295-related bulk drug substances, PCAC December 4, 2024

Human evidence· 2

In healthy adults given CJC‑1295, no serious adverse reactions were reported.
Randomized controlled trialn not reported
In online forum threads, users raised concerns about female consequences of CJC‑1295 use, including dosage estimation, cycling and long-term consequences.
Observational studyn not reported

Doses studied · 5

The doses that these studies used. They are not recommendations.

60 or 90 microg/kgHuman
Species
human
Route
injection
Duration
Not reported
Design
Non-randomized trial
2 microg every 24 hAnimal
Species
mouse
Route
Not reported
Duration
5 weeks
Design
Animal study (in vivo)
2 microg every 48 h or 72 hAnimal
Species
mouse
Route
Not reported
Duration
5 weeks
Design
Animal study (in vivo)
2 microg every 24 h or 48 hAnimal
Species
mouse
Route
Not reported
Duration
5 weeks
Design
Animal study (in vivo)
2 microg every 24 h, 48 h or 72 hAnimal
Species
mouse
Route
Not reported
Duration
5 weeks
Design
Animal study (in vivo)

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
60 or 90 microg/kg	Human	human	injection	Not reported	Non-randomized trial
2 microg every 24 h	Animal	mouse	Not reported	5 weeks	Animal study (in vivo)
2 microg every 48 h or 72 h	Animal	mouse	Not reported	5 weeks	Animal study (in vivo)
2 microg every 24 h or 48 h	Animal	mouse	Not reported	5 weeks	Animal study (in vivo)
2 microg every 24 h, 48 h or 72 h	Animal	mouse	Not reported	5 weeks	Animal study (in vivo)

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000009
Peptide version: 8
Peptide hash: a92dc241e08930fa…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256657
22 Oct 2026UpdatedData version 254502
21 Oct 2026UpdatedData version 213603
14 Oct 2026UpdatedData version 194681
13 Oct 2026UpdatedData version 173531
12 Oct 2026UpdatedData version 165106

For developers

curl -s https://pepbank.io/v1/briefs/cjc-1295

Evidence summary for CJC-1295 (with DAC): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Growth hormone and IGF-1Endocrine and hormones	Human: 16 results from 3 studies: 9 increase, 2 decrease, 4 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 10 results from 3 studies: 9 increase, 1 decrease. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: In vitro (cells)	No results	27
Patterns of useWhole body	Human: 2 results from 1 study: 2 not reported. Strongest design: Observational study	No results	No results	No results	2
PharmacokineticsPharmacology	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	Animal: 5 results from 3 studies: 1 no significant change, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: In vitro (cell-free)	No results	7
Adverse eventsWhole body	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1
Body weightMetabolic and weight	No results	Animal: 4 results from 1 study: 2 increase, 2 no significant change. Strongest design: Animal study (in vivo)	No results	No results	4
Bone and jointMusculoskeletal	No results	Animal: 1 result from 1 study: 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	1
Receptor activity and mechanismPharmacology	No results	No results	Lab: 1 result from 1 study: 1 decrease. Strongest design: Other design	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Growth hormone and IGF-1Endocrine and hormones	Human: 16 results from 3 studies: 9 increase, 2 decrease, 4 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 10 results from 3 studies: 9 increase, 1 decrease. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: In vitro (cells)	No results	27
Patterns of useWhole body	Human: 2 results from 1 study: 2 not reported. Strongest design: Observational study	No results	No results	No results	2
PharmacokineticsPharmacology	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	Animal: 5 results from 3 studies: 1 no significant change, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: In vitro (cell-free)	No results	7
Adverse eventsWhole body	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1
Body weightMetabolic and weight	No results	Animal: 4 results from 1 study: 2 increase, 2 no significant change. Strongest design: Animal study (in vivo)	No results	No results	4
Bone and jointMusculoskeletal	No results	Animal: 1 result from 1 study: 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	1
Receptor activity and mechanismPharmacology	No results	No results	Lab: 1 result from 1 study: 1 decrease. Strongest design: Other design	No results	1

CJC-1295 (with DAC) studies and research data

CJC-1295 identity

Targets

Sequence and structure

Sequence

Alignment to Somatorelin, human GHRH(1-44)

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

CJC-1295 results by year and outcome

What the studies measured

CJC-1295 studies on growth hormone and growth

CJC-1295 studies on use, access and costs

CJC-1295 studies on blood levels and clearance

CJC-1295 studies on side effects

CJC-1295 studies on weight and appetite

CJC-1295 studies on bones and joints

CJC-1295 studies on receptors and cell signals

CJC-1295 trials

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

Papers

Studies with results

Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.

Advances in the detection of growth hormone releasing hormone synthetic analogs.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.

The study of doping market: How to produce intelligence from Internet forums.

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Newer studies

CJC-1295 (with DAC) studies: 21 papers with results

Regulatory and safety

Human evidence· 2

Doses studied · 5

Data and API

Peptide

Latest changes

For developers

Compare

Related peptides

CJC-1295 results by year and outcome

CJC-1295 studies on growth hormone and growth

CJC-1295 studies on use, access and costs

CJC-1295 studies on blood levels and clearance

CJC-1295 studies on side effects

CJC-1295 studies on weight and appetite

CJC-1295 studies on bones and joints

CJC-1295 studies on receptors and cell signals

CJC-1295 trials

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

Papers

Studies with results

Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.